| Document |
Document Title |
|
WO/2016/111357A1 |
The present invention is directed to the compound (1S)-2-acetyl-1-(4-chloro-2-methoxyphenyl)-5-fluoro-1,2,3,9-
tetrahydrospiro[ß-carboline-4,1'-cyclopropane] represented by the formula. This compound, when compared to conventionally-kno...
|
|
WO/2016/105190A1 |
The present invention relates to the use of an oxytocin receptor antagonist in females undergoing embryo transfer as part of an assisted reproductive technology. In particular, methods are provided for increasing ongoing implantation rat...
|
|
WO/2016/095650A1 |
Disclosed are an A-type polymorphic substance of yonkenafil hydrochloride, a preparation method therefor, and a composition and use thereof. A powder diffraction pattern of the A-type polymorphic substance of yonkenafil hydrochloride com...
|
|
WO/2016/095778A1 |
A method for treatment and prevention of air pollution-related diseases, especially diseases related to atmospheric PM2.5 in subjects. The method comprises administering an effective amount of a polyunsaturated fatty acid and vitamin E t...
|
|
WO/2016/097013A1 |
The present invention relates to substituted Pyridyl-cycloalkyl- carboxylic acids of general formula (I), to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a phar...
|
|
WO/2016/100086A1 |
Methods and materials for treating bacterial vaginosis ("BV") are provided. Cervicovaginal secretions ("CVS") from a woman with Lactobacillus crispatus-dominated (>50%) vaginal microbiota is transplanted to women with BV as a method for ...
|
|
WO/2016/093326A1 |
Provided is a medicinal composition for treating and preventing an angiogenic disease, said medicinal composition comprising a cancer antigen peptide.
|
|
WO/2016/090701A1 |
Disclosed is a long-acting ovulation promoting injection. The long-acting ovulation promoting injection comprises a follicle-stimulating hormone fusion protein and a pharmaceutically acceptable carrier. The content of the follicle-stimul...
|
|
WO/2016/084816A1 |
Provided is a bicyclic compound having an inhibitory effect on acetyl-CoA carboxylase. A compound represented by the formula: (in the formula, each of the symbols is as defined in the specification) or a salt thereof has an inhibitory ef...
|
|
WO/2016/084070A1 |
A method of treating uterine fibroid in a subject in need thereof is provided. The method comprising administering to the subject a therapeutically effective amount of pigment epithelium-derived factor (PEDF), thereby treating the uterin...
|
|
WO/2016/081592A1 |
Novel antimicrobial compositions comprise at least a form of a fosfomycin (or suitable analogs, or derivatives thereof), and at least one sulfonamide (or suitable analogs, or derivatives thereof), and/or at least one diaminopyridine (or ...
|
|
WO/2016/074117A1 |
A pharmaceutical composition for treating deficiency of the kidney and a preparation method therefor. The pharmaceutical composition is prepared by using the following raw materials: 30 to 50 parts of cinnamon, 30 to 50 parts of platycla...
|
|
WO/2016/071283A1 |
Provided is a compound for use in medicine for inhibiting tryptophan-2,3-dioxygenase (TDO) and/or indoleamine-2,3-dioxygenase (IDO), which compound comprises formula (I) wherein X1, X2, and X7, may be the same or different and each is in...
|
|
WO/2016/070815A1 |
Disclosed in the present invention is a class of new type growth hormone releasing hormone-like peptide. The growth hormone releasing hormone-like peptide is in the form of homodimer and has a relatively high releasing activity of pituit...
|
|
WO/2016/029669A9 |
The present invention relates to a photo-hexyl ether compound, and a pharmaceutical composition and usage thereof. Particularly, the present invention relates to 2(4)-(1-hexyloxyethyl)-6,7-dipropionate-1,3,5,8-tetramethyl-
4(2)-vinylporp...
|
|
WO/2016/068208A1 |
Provided are: a medicine for improving the state of pregnancy, which comprises a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient; and a use of the medicine.
|
|
WO/2016/069578A1 |
The present invention relate to bromodomain inhibitor compounds, pharmaceutical compositions comprising the bromodomain inhibitor compounds and methods of treating a disorder responsive to fee modulation of a BET family polypeptide using...
|
|
WO/2016/067956A1 |
The present invention provides a microneedle device comprising a base plate, microneedles arranged on the base plate, and coating layers respectively formed on the microneedles, wherein each of the coating layers contains recombinant fol...
|
|
WO/2016/066058A1 |
Provided is a topical Chinese medicinal composition for treating mastitis, said Chinese medicinal composition being made of raw powders or extracts of the following Chinese medicinal materials: 15-20 g of Szechuan lovage, 15-30 g of whit...
|
|
WO/2016/063933A1 |
Provided is a heterocyclic compound that has an excellent RBP4 reducing effect and is useful as a preventive or therapeutic drug for diseases or symptoms mediated by a rise in RBP4 or by retinol supplied by RBP4. A compound represented b...
|
|
WO/2016/060539A1 |
The invention relates to strains of Lactobacillus brevis, LbH2, LbH3, LbH5, LbH9 and LbH13, isolated from the juice of Agave salmiana and the method for the isolation thereof, wherein said strains have bile salt hydrolase (SBH) activity ...
|
|
WO/2016/058194A1 |
A traditional Chinese medicine composition for treating menopausal syndrome, and a preparation method for same, the components and parts by weight of the composition being: 95-105 parts Fallopia multiflora, 115-125 parts Fructus ligustri...
|
|
WO/2016/027163A9 |
Systems, compositions, devices, and methods for treating a mammary condition in a mammal using gNO delivered from a nitric oxide releasing solution (NORS) are disclosed and described. In one embodiment, the mammary condition may be masti...
|
|
WO/2016/055681A1 |
The invention relates to the processing and use of fluids of the reproductive tract (biofluids) for improving the in vitro production of embryos of mammals, comprising the following steps: fractionating and processing the biofluids by me...
|
|
WO/2016/054741A1 |
The invention relates to a microsphere composition comprising (a) a microsphere material; and (b) a lipidic liquid formulation comprising (i) an effective amount of a progestogen, and (ii) vitamin E or an analog of vitamin E, incorporate...
|
|
WO/2016/056001A1 |
The present invention relates to a composition for intravaginal and/or for internal mucosal application, comprising an effective amount of a sulfated polysaccharide, one or more of a natural quaternary polymer, a quaternary molecular com...
|
|
WO/2016/052573A1 |
[Problem] The objective of the present invention is to provide a formulation technique with which hardening of a capsule coating over time can be suppressed in a capsule that is formed by filling contents, which include an anthocyanin, a...
|
|
WO/2016/053092A1 |
The present invention provides an orally disintegrating solid pharmaceutical dosage unit having a weight between 50 and 1,000 mg, said dosage unit consisting of: ∙ 1-100 wt.% of particles consisting of: - 0.01-10wt.% of a partus contro...
|
|
WO/2016/042451A1 |
The present invention provides compounds of formula (I) and in particular 2-[bis(4-fluorophenyl)methyl]-2,7- diazaspiro[4.5]decan-10-one derivatives and related compounds as inhibitors of human dopamine-active-transporter (DAT) protein f...
|
|
WO/2016/041255A1 |
A traditional Chinese medicine composition capable of enriching yin, nourishing kidney and nourishing qi. The formula comprises the following ingredients: 5 to 15 g of codonopsis pilosula, 8 to 15 g of black soyabean coats, 15 to 25 g of...
|
|
WO/2016/044447A1 |
There are described imidazole and pyrazole derivatives which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorder...
|
|
WO/2016/038308A1 |
The invention relates to antibodies directed against follicle-stimulating hormone (FSH) and capable of potentiating the bioactivity of gonadotropins.
|
|
WO/2016/038309A1 |
The invention relates to antibodies directed against follicle-stimulating hormone (FSH) and capable of potentiating the bioactivity of gonadotropins.
|
|
WO/2016/038310A1 |
The present invention relates to an antibody against the follicle-stimulating hormone (FSH), said antibody being capable of potentializing FSH and CG bioactivity.
|
|
WO/2016/037424A1 |
A medicinal liquor and a preparation method therefor. The medicinal liquor is characterized by being prepared with the following raw materials: codonopsis pilosula, black soybean coat, date, rhizoma polygonatum, dried tangerine peel, spa...
|
|
WO/2016/036093A1 |
The present disclosure relates to compositions for preparing an oral dispersible film comprising tadalafil or its pharmaceutically acceptable salt thereof, surfactant, plasticizer and sweetening agent; an oral dispersible film; and metho...
|
|
WO/2016/030901A1 |
The present invention relates to compositions and methods for preventing premature follicle activation and loss induced by acute insults, such as, medical treatment, a disease or a disorder, thereby preserving fertility in a subject.
|
|
WO/2016/033287A1 |
The present disclosure relates to methods of collecting cervical-vaginal fluid exosomes and microvesicles and isolating corresponding mRNA. In particular, certain embodiments relate to the method of collecting the cervical-vaginal fluids...
|
|
WO/2016/031987A1 |
A compound represented by any of formulas (Ia)-(Ic) or formula (II), or a pharmaceutically acceptable salt thereof. (In the formulas, R1, R2, R3, R4a, R4c, R5, R15, ring A, X1, and X2 are as defined in the specification.)
|
|
WO/2016/028971A1 |
The present invention provides compounds of Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This inven...
|
|
WO/2016/028045A1 |
The present invention relates to a veterinary composition for prevention and treatment of sterility using a mixed herbal extract, an animal feed additive, and a feed comprising the same. Morinda officinalis How, Cuscutae Semen and/or an ...
|
|
WO/2016/027228A1 |
A pharmaceutical composition or dietary supplement with antioxidant activity, mood- regulating activity and insulin-sensitizing activity, with a consequent reduction of the accumulation of adipose tissue, is described, for use in the pre...
|
|
WO/2016/028979A1 |
Excipient compositions including a combination of excipients for mucoadhesive pharmaceutical compositions that improve mucoadhesiveness power, as well as release of and adhesion time of suitable active pharmaceutical ingredients (APIs) a...
|
|
WO/2016/026772A1 |
Provided is a tryptophan-2,3-dioxygenase (TDO) and/or indoleamine-2,3-dioxygenase (IDO) inhibitor compound for use in medicine, which compound comprises the following formula (I): wherein X1 is selected from C and N; X3 and X5 may be the...
|
|
WO/2016/028225A1 |
The present invention relates to platinum compounds of Formula (I) or (II) as defined herein as well as their use for the treatment of cancer, methods for treating cancer in a subject using said compounds, and methods for triggering apop...
|
|
WO/2016/026474A1 |
The present invention provides new strains of lactobacilli, producing substances effective against vaginal pathogens, Lactobacillus crispatus CCM 7997; Lactobacillus reuteri CCM 7998; Lactobacillus crispatus CCM 8522; Lactobacillus ferme...
|
|
WO/2016/025541A1 |
The invention provides compositions and methods for the prevention, treatment, or management of sexual dysfunction, such as premature ejaculation. The method comprises administering an effective amount of curcuminoid containing compositi...
|
|
WO/2016/025669A1 |
The present application relates to certain difluoropyrrolidine compounds, pharmaceutical compositions containing them, and methods of using them, including methods for treating substance addiction, panic disorder, anxiety, post-traumatic...
|
|
WO/2016/021508A1 |
The present invention provides an epitope peptide derived from CDCA1 and having a cytotoxic T-cell induction ability. The present invention also provides: a polynucleotide for coding the peptide; an antigen-presenting cell presenting the...
|
|
WO/2016/003327A9 |
The use of 3-(3-[1,2,4]-triazolo)-oxatriazolium-5-olate for treating sexual disorders. The invention relates to the chemical and pharmaceutical industry, and more particularly to the creation of a novel agent for treating sexual disorder...
|
